IPO Year:
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|
3/A - SS Innovations International, Inc. (0001676163) (Issuer)
3 - SS Innovations International, Inc. (0001676163) (Issuer)
8-K - SS Innovations International, Inc. (0001676163) (Filer)
8-K - SS Innovations International, Inc. (0001676163) (Filer)
SCHEDULE 13G/A - SS Innovations International, Inc. (0001676163) (Subject)
SCHEDULE 13G/A - SS Innovations International, Inc. (0001676163) (Subject)
8-K - SS Innovations International, Inc. (0001676163) (Filer)
10-Q - SS Innovations International, Inc. (0001676163) (Filer)
8-K - SS Innovations International, Inc. (0001676163) (Filer)
8-K - SS Innovations International, Inc. (0001676163) (Filer)
8-K - SS Innovations International, Inc. (0001676163) (Filer)
FORT LAUDERDALE, Fla., May 27, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the "Company" or "SS Innovations") (NASDAQ:SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the Company's SSi Mantra surgical robotic system has been utilized to successfully perform more than 4,000 robotic surgeries across more than one hundred types of surgeries without any complications, injuries or mortalities. Of note, this milestone includes approximately 215 cardiac surgical procedures, of which six were successfully performed via telesurgery across India with the SSi Mantr
Record Quarterly Revenue of $5.1 Million Driven by Higher SSi Mantra 3 Unit SalesOn Track for July 2025 De Novo Application to the FDA for SSi Mantra 3 FORT LAUDERDALE, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the "Company" or "SS Innovations") (NASDAQ:SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three months ended March 31, 2025. The Company also filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, with the Securities and Exchange Commission on May 14, 2025. First Quarter
FORT LAUDERDALE, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the "Company" or "SS Innovations") (NASDAQ:SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the Company is planning to submit a De Novo Classification Request to the U.S. Food and Drug Administration (the "FDA") for the SSi Mantra 3 surgical robotic system (the "SSi Mantra 3") in July 2025. If approved by the FDA, the SSi Mantra 3 would be cleared to market in the United States. Submission of the De Novo Classification Request does not guarantee FDA approval. Since the Compan
FORT LAUDERDALE, Fla., May 05, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the "Company" or "SS Innovations") (NASDAQ:SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today reiterated guidance for the first quarter of 2025. Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, "Following our recent uplisting to Nasdaq, we remain very pleased with the growth trajectory of our business as we conclude the first quarter of 2025 and enter the second quarter. We believe that we are well-positioned to maintain this momentum and achi
FORT LAUDERDALE, Fla., May 02, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the "Company" or "SS Innovations") (NASDAQ:SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced the appointment of Arvind Palaniappan as the Company's Interim Chief Financial Officer, effective May 1, 2025, pursuant to a planned leadership transition. Anup Sethi, SS Innovations' departing CFO, will remain available to advise the Company prior to the appointment of a permanent CFO. SS Innovations has commenced a search process to identify and recruit a permanent successor for the CFO role
FORT LAUDERDALE, Fla., May 02, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the "Company" or "SS Innovations") (NASDAQ:SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced the appointment of Arvind Palaniappan as the Company's Interim Chief Financial Officer, effective May 1, 2025, pursuant to a planned leadership transition. Anup Sethi, SS Innovations' departing CFO, will remain available to advise the Company prior to the appointment of a permanent CFO. SS Innovations has commenced a search process to identify and recruit a permanent successor for the CFO role